Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

46 results about "Her Disease" patented technology

Method for determining a predictive function for discriminating patients according to their disease activity status

The invention relates to a method for determining a predictive function for discriminating patients according to their disease activity status, comprising steps of: a—measuring values of biological markers for each patient of a first group of patients having a first known disease activity status, and for each patient of a second group of patients having a second known disease activity status, the measured values forming a dataset b—analyzing the dataset for identifying biological markers which are differentially expressed between the first group of patients and the second group of patients, c—among the biological markers identified at step b, determining correlated markers as markers which are correlated with other markers above a predetermined significance level, d—removing from the dataset, values measured for a biological marker identified as correlated marker, e—analyzing the dataset obtained at step d for determining a predictive function that predicts a disease activity status of a patient as a combination of values of biological markers, f—evaluating an accuracy index associated with the predictive function determined at step e, g—repeating steps d to f by selectively removing from the dataset, values measured for one or several biological marker(s) identified as correlated marker(s), so as to gradually decrease the number of biological markers in the combination of value until the accuracy index reaches an expected level.
Owner:CENT NAT DE LA RECHERCHE SCI

Method for Prolonging the Action on Acupuncture Points Including for Reducing the Excessive Body Weight and for Correcting the Body, a Device and a Needle (Variants) for Carrying Out Said Method

InactiveUS20080215080A1Efficient reductionSufficiently correctingAcupunctureSurgical needlesNeedle freeHer Disease
The invention relates to medicine, in particular to acupuncture reflexotherapy. The inventive method consists in introducing a needle provided with a volume, plate or annular-shaped head into one of the predetermined, for example, auricular acupuncture points of a patient, wherein taking it through under the skin, the needle free end is withdrawn from the other predetermined point and a detachable retainer having plate or volume shape is secured thereon. The retainer can also be designed non-detachable and be formed by a bended free end of the needle rod. A required rate of lowering an excessive body weight is provided by exposure the zones of the indicated points to the head and/or retainer weight, or/and by changing a contact area thereof with the indicated points, and/or by a progradient correlation of intensity of the action on these points. In order to enhance the effect, pins and suspension members are used on the head and/or the retainer, as well as a contoured and/or wave-shaped surface of the needle rod. The proposed method and the needle design allow for a more efficient action on the selected acupuncture points, thereby significantly reducing the patient's excessive body weight or treating his or her diseases.
Owner:FREY MEDICAL TECH AG

Assays for cancer patient monitoring based on levels of epidermal growth factor receptor (EGFR) extracellular domain (ECD) analyte, alone or in combination with other analytes, in body fluid samples

The present invention describes clinically and medically important methods of monitoring the outcome of a cancer patient who is suffering from disease or who is undergoing treatment or therapy for his or her disease. More specifically, the invention provides a method of monitoring the progression of disease or cancer treatment effectiveness in a cancer patient by measuring the level of the extracellular domain (ECD) of the epidermal growth factor receptor (EGFR) in a sample taken from the cancer patient, preferably, before treatment, at the start of treatment, and at various time intervals during treatment, wherein a decrease in the level of the ECD of the EGFR in the cancer patient compared with the level of the ECD of the EGFR in normal control individuals serves as an indicator of cancer advancement or progression and / or a lack of treatment effectiveness for the patient. As another aspect of determining disease outcome and survival, the invention further provides assessing both EGFR and HER-2 / neu levels, in combination, in a patient sample. A finding of decreased levels of EGFR concomitantly with elevated or increased levels of HER-2 / neu relative to control levels indicates poor outcome and short time to progression.
Owner:SIEMENS HEALTHCARE DIAGNOSTICS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products